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Diagnosis and 
Treatment of 
Tuberculosis in 
the Private Sector, 
Vietnam 
To the Editor: In many countries, 
the private sector (practitioners 
not employed by government and 
nongovernment institutions, e.g., 
hospitals, pharmacies) is a major 
source of care, even for poor 
persons, and the area where services 
for the public are widely available 
(1,2). However, little information 
is available from high-incidence 
countries about the role of the private 
sector in tuberculosis (TB) detection 
and treatment (3). In Vietnam, <40% 
of all TB cases in Ho Chi Minh City 
(the largest city in Vietnam and with 
the highest rate of economic growth 
in the country) were estimated to be 
treated in the private sector (4), and 
half of all patients with a diagnosis 
of TB in the public sector (National 
Tuberculosis Program [NTP]) in Ho 
Chi Minh City initially sought help in 
the private sector (5). However, this 
estimate does not reﬂ  ect private care 
in the entire country.
In 2006–2007, a countrywide 
TB prevalence survey was conducted 
in Vietnam (6) in which data were 
obtained for previous TB treatment. 
This survey provided an opportunity 
to calculate a nationally representative 
estimate of the proportion of TB 
cases treated in the private sector 
and to investigate demographic 
characteristics of persons choosing 
treatment in this sector.
The study was reviewed and 
approved by the Research Board of 
the Vietnam National Lung Hospital. 
Details of survey methods have been 
reported (6). All eligible persons were 
screened to identify suspected cases 
of TB by using a short, structured, 
screening questionnaire and chest 
radiograph. Persons with suspected 
TB were those who reported per-
sistent productive cough, who had 
radiographic abnormalities suggestive 
of TB, or who received TB treatment 
either currently or in the 2 years 
preceding the survey. Persons had 
an in-depth interview that included 
questions on where they were treated 
for TB. Assessment of socioeconomic 
status was based on 9 household 
characteristics (7).
Missing data were imputed by 
using multiple imputation methods, 
assuming that these data were 
missing at random to adjust for 
nonparticipation and missing data 
on facility of TB treatment (8). We 
used the ice and mi commands in 
Stata version 11 software (StataCorp 
LP, College Station, TX, USA), 
which included age, area, zone, and 
socioeconomic status.
Of the 103,924 eligible persons 
in selected districts, 94,179 (91%) 
were screened, 7,498 were identiﬁ  ed 
as having suspected TB, and 407 
reported having been recently treated 
for TB: 316 (77.6%) in public 
health facilities (PHFs) reporting 
cases to the NTP, 8 (2.0%) in PHFs 
not reporting cases to the NTP, and 
29 (7.1%) in private health care 
facilities not reporting to the NTP. 
Fifty-four (13.3%) did not provide 
information about where they were 
treated. Multiple imputation led to 
adjusted proportions of 88.9%, 2.9%, 
and 8.2%, respectively. Sensitivity 
analyses, which assigned 54 persons 
with missing data for location of TB 
treatment to PHFs or private clinics, 
resulted in a range of 7.1%–20.3% 
for private sector treatment.
Characteristics of participants by 
type of facility where they received 
TB treatment are shown in the 
Table. Women, younger persons, and 
residents of southern Vietnam were 
more likely to seek treatment in the 
private sector. Urban populations and 
those with the highest socioeconomic 
status were most likely to seek private 
care, but these differences were not 
signiﬁ  cant (Table).
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We estimated that 8.2% of persons 
with TB in Vietnam were treated in 
private clinics. Although sensitivity 
analysis showed a wide range around 
this estimate (7.1%–20.3%), our 
data suggest that private health care 
facilities treat a large proportion of TB 
patients. Use of the private sector was 
relatively high in southern Vietnam 
(11.7%), especially in southern urban 
areas (13.3%).
Taking into account observed 
patterns in our study (i.e., preference 
for private sector treatment among 
young persons, higher income groups, 
and those in urban areas) and general 
development in Vietnam, we expect 
that the private sector will provide 
increased diagnosis and treatment 
of TB. With availability of TB drugs 
in private pharmacies, (9) improved 
private TB care is needed (10) by 
establishing better collaboration and 
coordination between the NTP and 
the private sector through the public–
private approach (4) and by improving 
and expanding reporting systems so 
that all facilities where TB patients are 
diagnosed and treated are included.
A strength of our study is that it 
included a nationally representative 
sample of previously treated TB 
patients because all who reported 
having been treated recently for 
TB were deﬁ   ned as persons with 
suspected TB. A limitation of our 
study is that it depended on self-
reported TB treatment, which is prone 
to recall bias and has potentially led 
to underestimation because some 
participants may not have been 
accurate regarding previous or current 
episodes of TB and private sector 
treatment because of social desirability 
bias. The NTP in Vietnam needs 
to implement and improve public–
private mix projects, and private 
practitioners need to be appropriately 
trained to report TB patients according 
to NTP guidelines.
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Table. Characteristics of patients treated for tuberculosis at time of prevalence survey (2006–2007) or in 2 preceding years, Vietnam*
Characteristic
Public health facilities 
reporting to NTP, no. (%) 
Public health facilities  
not reporting to NTP, no. (%)  Private sector, no. (%)  OR (95% CI) 
Total 316 (89.5)  8 (2.3)  29 (8.2)  NA†
Sex
  M  230 (92.4)  4 (1.6)  15 (6.0)  1
  F  86 (82.7)  4 (3.8)  14 (13.5)  2.4‡ (1.0–5.6) 
Age, y 
  15–35  51 (79.7)  2 (3.1)  11 (17.2)  3.1 (1.3–7.4) 
  35–55  134 (93.1)  4 (2.8)  6 (4.2)  0.4 (0.1–0.9) 
  >55  131 (90.3)  2 (1.4)  12 (8.3)  1.0 (0.4–2.3) 
Area 
  Urban  95 (85.6)  2 (1.8)  14 (12.6)  2.2 (0.9–5.1) 
  Remote  59 (89.4)  2 (3.0)  5 (7.6)  0.9 (0.3–2.5) 
  Rural  162 (92.0)  4 (2.3)  10 (5.7)  0.5 (0.2–1.2) 
Zone 
  Northern  117 (93.6)  5 (4.0)  3 (2.4)  0.2 (0.0–0.7) 
  Central  50 (87.7)  1 (1.8)  6 (10.5)  1.4 (0.4–3.8) 
  Southern  149 (87.1)  2 (1.2)  20 (11.7)  2.5 (1.1–6.5) 
Socioeconomic status§ 
  Lowest  104 (91.2)  2 (1.8)  8 (7.0)  0.8 (0.3–1.9) 
  Medium  85 (90.4)  2 (2.1)  7 (7.4)  0.9 (0.3–2.2) 
  Highest  103 (88.0)  2 (1.7)  12 (10.3)  1.5 (0.6–3.5) 
  No information  24 (85.7)  2 (7.1)  2 (7.1)  NA¶
*NTP, National Tuberculosis Program; OR, odds ratio, CI, confidence interval; NA, not available. 
†Not available because >4 categories are needed for calculation of OR.  
‡For difference between private and public sectors. All other comparisons were for differences between 1 group and the other groups combined. 
§Based on a set of indicators (7) and expressed by tertiles of expenditure distribution among all survey participants. 
¶Not available because there were only 28 persons with no information. LETTERS
DOI: 10.3201/eid1703.101468
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Fluoroquinolone-
Resistant 
Mycobacterium 
tuberculosis, 
Pakistan, 2005–2009
To the Editor: Pakistan is 1 of 22 
countries listed by the World Health 
Organization (WHO) as having a high 
incidence of tuberculosis (TB). We 
recently reported an increase in rates 
of multidrug-resistant (MDR) TB 
with emergence of extensively drug-
resistant TB (1). Fluoroquinolone 
resistance is associated with worse 
outcome in patients with MDR 
TB (2). Recent evidence suggests 
emergence and increasing incidence 
of  ﬂ  uoroquinolone-resistant  Myco-
bacterium tuberculosis from several 
countries, particularly in MDR strains 
(3). We present data from a tertiary 
care referral center laboratory in 
Pakistan to assess ﬂ  uoroquinolone 
resistance in MDR TB strains during 
2005–2009.
The Aga Khan University Hospital 
and its clinical laboratory have been 
accredited by the Joint Commission 
of International Accreditation and 
designated as a technical partner of the 
National TB Program. M. tuberculosis 
susceptibility testing is also 
periodically validated by the WHO 
Supranational Reference Laboratory 
network. The microbiology laboratory 
serves different cities across Pakistan 
with  ≈180 peripheral collection 
units. Specimens for TB cultures are 
requested by physicians and received 
through passive collection and thus are 
not restricted to programmed surveys. 
All specimens received at each of the 
collection units are sent to the central 
laboratory in Karachi for culture and 
drug susceptibility testing (DST). 
Specimens reach the main laboratory 
within 24 hours after receipt.
During the past 4 years, the 
laboratory has received 12,000–
15,000 specimens annually for M. 
tuberculosis culture; positivity rate 
has been 15%–20%. Culture and DST 
are performed at the laboratory in 
accordance with Clinical Laboratory 
Standards Institute and WHO 
recommendations, as described (4). 
During 2005–2008, ﬂ  uoroquinolone 
susceptibilities for all MDR and 
polydrug-resistant isolates were 
determined by using ciproﬂ  oxacin 
(2  μg/mL). From 2009 onwards, 
ﬂ   uoroquinolone susceptibilities were 
determined by using oﬂ  oxacin  (2 
μg/mL), and second-line DST was 
performed for all M. tuberculosis 
isolates.
During 2005–2009, a total of 
11,263 cultures were reported positive 
for M. tuberculosis. Of these, 34.4% 
were MDR, and 50.1% were sensitive 
to all 4 ﬁ   rst-line agents (isoniazid, 
rifampin, pyrazinamide, ethambutol). 
Because of inconsistencies in 
testing criteria for ﬂ  uoroquinolones 
(ﬂ   uoroquinolone testing being 
conducted primarily for MDR cases 
during 2005–2008), the overall 
ﬂ  uoroquinolone-resistance  rate 
could not be determined. However, 
for MDR strains, ﬂ  uoroquinolone 
susceptibilities were consistently 
determined, and resistance rates 
increased from 17.41% in 2005 to 
42.92% in 2009 (p<0.001, by χ2 test 
for trend analysis) (Table).
A progressive increase in 
ﬂ  uoroquinolone use and its association 
with increase in resistance against 
organisms other than M. tuberculosis 
have been reported from Pakistan 
(5). We report a progressive increase 
in  ﬂ   uoroquinolone resistance rate 
in MDR M. tuberculosis isolates 
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